ADAP - アダプティミュ―ン・セラピュ―ティクス (Adaptimmune Therapeutics plc) アダプティミュ―ン・セラピュ―ティクス

 ADAPのチャート


 ADAPの企業情報

symbol ADAP
会社名 Adaptimmune Therapeutics PLC (アダプティミュ―ン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets find and genetically engineer TCR and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials which are directed to cancer testis antigens NY-ESO-1 MAGE-A4 and MAGE-A10.   アダプティミュ―ン・セラピュ―ティクスは、英国のバイオ医薬品企業。独自のT細胞レセプタ―・プラットフォ―ムによる新しい癌免疫治療製品の開発に焦点を当て事業を展開。主な製品候補には、癌抗原として親和性が強化されたT細胞レセプタ―治療薬のNY-ESO-1およびNY-ESOがある。   Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
本社所在地 60 Jubilee Avenue Milton Park Abingdon Oxfordshire OX14 4RY GBR
代表者氏名 James Julian Noble ジェームズジュリアンノーブル
代表者役職名 Chief Executive Officer Director 最高経営責任者(CEO)
電話番号 +44 1235-43-0000
設立年月日 41974
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 371人
url www.adaptimmune.com
nasdaq_url https://www.nasdaq.com/symbol/adap
adr_tso 66427089
EBITDA EBITDA(百万ドル) -84.89300
終値(lastsale) 13.2
時価総額(marketcap) 876837574.8
時価総額 時価総額(百万ドル) 1259.51
売上高 売上高(百万ドル) 48.68900
企業価値(EV) 企業価値(EV)(百万ドル) 1130.482
当期純利益 当期純利益(百万ドル) -92.72400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adaptimmune Therapeutics PLC - ADR revenues increased from $6.4M to $17.2M. Net loss increased 54% to $64.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 41% to $47.7M (expense) Other (expense) income net decrease from $3.7M (income) to $8.3M (expense).

 ADAPのテクニカル分析


 ADAPのニュース

   Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2022 Results - Earnings Call Transcript  2022/08/07 03:39:02 Seeking Alpha
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q2 2022 Earnings Conference Call Aug 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief…
   Adaptimmune Therapeutics: Q2 Earnings Insights  2022/08/04 13:41:09 Benzinga
Adaptimmune Therapeutics (NASDAQ: ADAP ) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus … Full story available on Benzinga.com
   Adaptimmune Therapeutics Earnings Beat, Revenue Misses In Q2 By Investing.com  2022/08/04 13:08:00 Investing.com
Adaptimmune Therapeutics Earnings Beat, Revenue Misses In Q2
   Adaptimmune Q2 2022 Earnings Preview (NASDAQ:ADAP)  2022/08/03 16:05:00 Seeking Alpha
Adaptimmune (ADAP) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.The consensus EPS Estimate is -$0.29 (-625.0% Y/Y) and the consensus…
   Adaptimmune Therapeutics PLC: Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022  2022/07/21 12:00:00 Finanz Nachrichten
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report fi…
   Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022  2022/04/28 20:30:00 GlobeNewswire
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2022, before the US markets open on Monday, May 9, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.
   Adaptimmune in two-day rally thanks to Regeneron/Checkmate deal; shares up 15%  2022/04/20 15:37:14 Seeking Alpha
Adaptimmune Therapeutics (ADAP) is up 15% in trading on Wednesday and up ~21% since Mondays close.
   Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today  2022/04/19 19:43:02 The Motley Fool
Regeneron''s buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
   Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday  2022/04/11 20:40:37 The Motley Fool
Investors were not pleased that the company is preparing for a stock sale.
   Adaptimmune Therapeutics drops 5% on $400 mixed shelf offering (NASDAQ:ADAP)  2022/04/08 21:52:18 Seeking Alpha
Adaptimmune Therapeutics (ADAP) files for $400M mixed shelf securities of the registrant’s ADSs, warrants and units.Also files agreement prospectus supplement covering the…
   Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022  2022/04/28 20:30:00 GlobeNewswire
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2022, before the US markets open on Monday, May 9, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.
   Adaptimmune in two-day rally thanks to Regeneron/Checkmate deal; shares up 15%  2022/04/20 15:37:14 Seeking Alpha
Adaptimmune Therapeutics (ADAP) is up 15% in trading on Wednesday and up ~21% since Mondays close.
   Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today  2022/04/19 19:43:02 The Motley Fool
Regeneron''s buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
   Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday  2022/04/11 20:40:37 The Motley Fool
Investors were not pleased that the company is preparing for a stock sale.
   Adaptimmune Therapeutics drops 5% on $400 mixed shelf offering (NASDAQ:ADAP)  2022/04/08 21:52:18 Seeking Alpha
Adaptimmune Therapeutics (ADAP) files for $400M mixed shelf securities of the registrant’s ADSs, warrants and units.Also files agreement prospectus supplement covering the…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アダプティミュ―ン・セラピュ―ティクス ADAP Adaptimmune Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)